The HistoQuest software was used to quantify the number of G9a-positive cells (Figure 5a) showing that higher G9a expression was accompanied by increased tumor malignancy in DLBCL patients (p < 0.001) (Figure 5b), with higher G9a expression in DLBCL stages III and IV compared to the stage I and II samples (p < 0.001) (Figure 5c). Here, EHMT2 is linked to diffuse large B-cell lymphoma.